NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Lava provides business updates and reports fourth quarter and year-end financial results<
20 Mar 2024

Lava provides business updates and reports fourth quarter and year-end financial results

Strong balance sheet with cash of $95.6 million supports runway into 2026
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies<
20 Mar 2024

Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies

Proceeds to Support Advancement of Engrail’s Pipeline for Neuropsychiatric and Neurodevelopmental Disorder
Fusion Pharmaceuticals To Be Acquired By AstraZeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer<
19 Mar 2024

Fusion Pharmaceuticals To Be Acquired By AstraZeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer

Total transaction value of approximately $2.4 billion including the CVR
NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)<
21 Feb 2024

NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)

Study strengthens NST’s position as a multi-asset, clinical stage company
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders<
09 Feb 2024

Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders

This financing follows promising early clinical data from NRTX-1001 epilepsy program.
SparingVision Presents Initial SPVN06 Safety Data at the Macula Society 47th Annual Meeting<
08 Feb 2024

SparingVision Presents Initial SPVN06 Safety Data at the Macula Society 47th Annual Meeting

Enrollment and treatment of the third cohort, comprising three patients at a higher dose, are underway.
Mineralys Therapeutics Announces $120 Million Private Placement Financing<
08 Feb 2024

Mineralys Therapeutics Announces $120 Million Private Placement Financing

The financing was led by new investor TCGX and existing investor RA Capital Management
Inbiomotion and Source BioScience sign an exclusive agreement for MAF Test® in United Kingdom and Ireland<
08 Feb 2024

Inbiomotion and Source BioScience sign an exclusive agreement for MAF Test® in United Kingdom and Ireland

MAF Test® could increase the survival of 80% of the 56,000 early-stage breast cancer patients diagnosed each year.
Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy<
01 Feb 2024

Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy

Funding from French Government as part of the France Health Innovation Plan 2030 operated by Bpifrance
Lava Therapeutics announces collaboration with Merck & co., inc., Rahway, NJ, USA to evaluate Lava-1207 in combination with Keytruda®<
26 Jan 2024

Lava Therapeutics announces collaboration with Merck & co., inc., Rahway, NJ, USA to evaluate Lava-1207 in combination with Keytruda®

Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.